

CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

HIGHLIGHTS

3505 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

3507 **ALK Inhibitors in Neuroblastoma: A Sprint from Bench to Bedside**

Johannes H. Schulte and Angelika Eggert

See related article, p. 3543

3510 **Tamoxifen: Will Less Equal More in Women with Precancerous Breast Disease?**

Carol J. Fabian

See related article, p. 3576

3512 **How Accurately does PSMA Inhibitor 18F-DCFPyL-PET-CT Image Prostate Cancer?**

Lawrence D. True and Delphine L. Chen

See related article, p. 3674

CCR Drug Updates

3515 **FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a *FLT3* Mutation**

E. Dianne Pulte, Kelly J. Norsworthy, Yaping Wang, Qing Xu, Hisham Qosa, Ramadevi Gudi, Donna Przepiorka, Wentao Fu, Olanrewaju O. Okusanya, Kirsten B. Goldberg, R. Angelo De Claro, Ann T. Farrell, and Richard Pazdur

3522 **FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-small Cell Lung Cancer, A Collaborative Project Orbis Review**

Paz J. Vellanki, Flora Mulkey, Adnan A. Jaigirdar, Lisa Rodriguez, Yuan Xu, Hong Zhao, Jiang Liu, Grant Howe, Jian Wang, Qiuyi Choo, Sarah J. Golding, Victoria Mansell, Kwadwo Korsah, Dianne Spillman, R. Angelo de Claro, Richard Pazdur, Julia A. Beaver, and Harpreet Singh

Review

3528 **Thirty Years of HER3: From Basic Biology to Therapeutic Interventions**

Heidi M. Haikala and Pasi A. Jänne

Perspectives

3540 **Alternatives to Perpetual Chemotherapy for Metastatic Pancreatic Cancer**

Kim A. Reiss and Robert H. Vonderheide

RESEARCH BRIEFS: CLINICAL TRIAL BRIEF REPORTS

3543 **Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)**

A C

Jennifer H. Foster, Stephan D. Voss, David C. Hall, Charles G. Minard, Frank M. Balis, Keith Wilner, Stacey L. Berg, Elizabeth Fox, Peter C. Adamson, Susan M. Blaney, Brenda J. Weigel, and Yael P. Mossé

See related commentary, p. 3507

3549 **Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia**

Hui Zhang, Pengfei Wang, Zhuoyan Li, Yingyi He, Wenting Gan, and Hua Jiang

CLINICAL TRIALS: TARGETED THERAPY

3556 **First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors**

A C

George D. Demetri, Jason J. Luke, Antoine Hollebecque, John D. Powderly II, Alexander I. Spira, Vivek Subbiah, Louie Naumovski, Chris Chen, Hua Fang, Dominic W. Lai, Huibin Yue, Akshanth R. Polepally, James W. Purcell, Randy Robinson, Padmanee Sharma, James P. Allison, Anthony Tolcher, and Victor M. Villalobos

TABLE OF CONTENTS

3567 Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial

A C

Dapeng Li, Yihebal Chi, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan Cheng, Zhengang Xu, Xiangqian Zheng, Pingzhang Tang, and Ming Gao

3576 Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease

A C

Andrea DeCensi, Matteo Puntoni, Harriet Johansson, Aliana Guerrieri-Gonzaga, Silvia Caviglia, Franca Avino, Laura Cortesi, Antonio Ponti, Maria Grazia Pacquola, Fabio Falcini, Marcella Gulisano, Maria Digennaro, Anna Cariello, Katia Cagossi, Graziella Pinotti, Matteo Lazzeroni, Davide Serrano, Irene Maria Briata, Tania Buttiron Webber, Luca Boni, and Bernardo Bonanni

See related commentary, p. 3510

3584 Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors

Apostolia M. Tsimberidou, Philip A. Beer, Carrie A. Cartwright, Cara Haymaker, Henry H. Vo, Simin Kiany, Alexander R.L. Cecil, James Dow, Kemal Haque, Franck A. Silva, Lucy Coe, Helen Berryman, Elisabeth A. Bone, Graciela M. Nogueras-Gonzalez, David Vining, Hilary McElwaine-Johnn, and Ignacio I. Wistuba

3595 Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study

A C

Bastiaan M. Privé, Steffie M.B. Peters, Constantijn H.J. Muselaers, Inge M. van Oort, Marcel J.R. Janssen, J.P. Michiel Sedelaar, Mark W. Konijnenberg, Patrik Zámecnik, Maike J.M. Uijen, Melline G.M. Schilham, Annemarie Eek, Tom W.J. Scheenen, J. Fred Verzijlbergen, Winald R. Gerritsen, Niven Mehra, Linda G.W. Kerkmeijer, Robert J. Smeenk, Diederik M. Somford, Jean-Paul A. van Basten, Sandra Heskamp, Jelle O. Barentsz, Martin Gotthardt, J. Alfred Witjes, and James Nagarajah

3602 Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide

Johann S. de Bono, Mark T. Fleming, Judy S. Wang, Richard Cathomas, Manuel Selvi Miralles, John Bothos, Mary Jane Hinrichs, Qu Zhang, Peng He, Marna Williams, Anton I. Rosenbaum, Meina Liang, Kapil Vashisht, Song Cho, Pablo Martinez, and Daniel P. Petrylak

3610 Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance

Rana R. McKay, Lucia Kwak, Jett P. Crowdis, Jamie M. Sperger, Shuang G. Zhao, Wanling Xie, Lillian Werner, Rosina T. Lis, Zhenwei Zhang, Xiao X. Wei, Joshua M. Lang, Eliezer M. Van Allen, Rupal S. Bhatt, Evan Y. Yu, Peter S. Nelson, Glenn J. Bubley, R. Bruce Montgomery, and Mary-Ellen Taplin

CLINICAL TRIALS: IMMUNOTHERAPY

3620 Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spatalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bedard, Chia-Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine A. Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, and Aung Naing

3630 A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer

A C

Michael R. Shafiq, Terrence L. Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae E. Pastore, Crystal L. Mallow, Ernest Smith, Vikas Mishra, Andreas Schröder, Kevin M. Chin, Joseph T. Beck, Megan A. Baumgart, Ramaswamy Govindan, Nashat Y. Gabrail, Alexander I. Spira, Nagashree Seetharamu, Yanyan Lou, Aaron S. Mansfield, Rachel E. Sanborn, Jonathan W. Goldman, and Maurice Zauderer

3641 ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma

Katrina S. Pedersen, Nathan R. Foster, Michael J. Overman, Patrick M. Boland, Sunnie S. Kim, Kathryn A. Arrambide, Brandy L. Jaszewski, Tarios Bekaii-Saab, Rondell P. Graham, Jack Welch, Richard H. Wilson, and Robert R. McWilliams

3649 Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer—Results from Phase Ib Trial IMU.ACS.001

A C

Ursula Wiedermann, Erika Garner-Spitzer, Yee Chao, Marina Maglakelidze, Iurie Bulat, Arunee Dechaphunkul, Wichit Arpornwirat, Chaiyut Charoentum, Chia-Jui Yen, Thomas Cheung Yau, Suebpong Tanasanvimon, Jedzada Maneechavakajorn, Aumkhae Sookprasert, Li-Yuan Bai, Wen-Chi Chou, Teerapat Ungrakul, Mirjana Drinic, Joshua Tobias, Christoph C. Zielinski, Leslie Chong, Nicholas J. Ede, Mark T. Marino, and Anthony J. Good

TABLE OF CONTENTS

- 3661** **IFN α Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer**
Suzanne R. Thibodeaux, Brian B. Barnett, Srilakshmi Pandeswara, Shawna R. Wall, Vincent Hurez, Vinh Dao, Lishi Sun, Benjamin J. Daniel, Michael J. Brumlik, Justin Drerup, Álvaro Padrón, Teresa Whiteside, Ilona Kryczek, Weiping Zou, and Tyler J. Curiel

PRECISION MEDICINE AND IMAGING

- 3674** **Diagnostic Performance of ^{18}F -DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study**
A C Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel, and CONDOR Study Group
See related commentary, p. 3512
- 3683** **Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia**
A C Xiaojing Lin, Niu Qiao, Yang Shen, Hai Fang, Qing Xue, Bowen Cui, Li Chen, Hongming Zhu, Sujiang Zhang, Yu Chen, Lu Jiang, Shengyue Wang, Junmin Li, Bingshun Wang, Bing Chen, Zhu Chen, and Saijuan Chen
- 3695** **Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients**
Gian Maria Zaccaria, Luca Bertamini, Maria Teresa Petrucci, Massimo Offidani, Paolo Corradini, Andrea Capra, Alessandra Romano, Anna Marina Liberati, Donato Mannina, Paolo de Fabritiis, Nicola Cascavilla, Marina Ruggeri, Roberto Mina, Francesca Patriarca, Giulia Benevolo, Angelo Belotti, Gianluca Gaidano, Arnon Nagler, Roman Hájek, Andrew Spencer, Pieter Sonneveld, Pellegrino Musto, Mario Boccadoro, and Francesca Gay
- 3704** **Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET**
Jan-Michael Werner, Johannes Weller, Garry Ceccon, Christina Schaub, Caroline Tscherpel, Philipp Lohmann, Elena K. Bauer, Niklas Schäfer, Gabriele Stoffels, Christian Baues, Eren Celik, Simone Marnitz, Christoph Kabbasch, Gerrit H. Gielen, Gereon R. Fink, Karl-Josef Langen, Ulrich Herrlinger, and Norbert Galldiks

TRANSLATIONAL CANCER MECHANISMS AND THERAPY

- 3714** **A Low Tumor Mutational Burden and *PTEN* Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors**
A C Keigo Chida, Akihito Kawazoe, Masahito Kawazu, Toshihiro Suzuki, Yoshiaki Nakamura, Tetsuya Nakatsura, Takeshi Kuwata, Toshihide Ueno, Yasutoshi Kuboki, Daisuke Kotani, Takashi Kojima, Hiroya Taniguchi, Hiroyuki Mano, Masafumi Ikeda, Kohei Shitara, Itaru Endo, and Takayuki Yoshino
- 3725** **Targeted Deep Sequencing of Bladder Tumors Reveals Novel Associations between Cancer Gene Mutations and Mutational Signatures with Major Risk Factors**
Stella Koutros, Nina Rao, Lee E. Moore, Michael L. Nickerson, Donghyuk Lee, Bin Zhu, Larissa A. Pardo, Dalsu Baris, Molly Schwenn, Alison Johnson, Kristine Jones, Montserrat Garcia-Closas, Ludmila Prokunina-Olsson, Debra T. Silverman, Nathaniel Rothman, and Michael Dean
- 3734** **Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer**
Judit Börcsök, Miklos Diossy, Zsofia Sztupinszki, Aurel Prosz, Viktoria Tisza, Sandor Spisak, Orsolya Ruzs, Dag R. Stormoen, Helle Pappot, Istvan Csabai, Søren Brunak, Kent W. Mouw, and Zoltan Szallasi
- 3744** **Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30 $^{+}$ Malignancies**
Lucila N. Kerbauy, Nancy D. Marin, Mecit Kaplan, Pinaki P. Banerjee, Melissa M. Berrien-Elliott, Michelle Becker-Hapak, Rafet Basar, Mark Foster, Luciana Garcia Melo, Carly C. Neal, Ethan McClain, May Daher, Ana Karen Nunez Cortes, Sweta Desai, Francesca Wei Inng Lim, Mayela Carolina Mendt, Timothy Schappe, Li Li, Hila Shaim, Mayra Shanley, Emily L. Ensley, Nadima Uprety, Pamela Wong, Enli Liu, Sonny O. Ang, Rong Cai, Vandana Nandivada, Vakul Mohanty, Qi Miao, Yifei Shen, Natalia Baran, Natalie W. Fowlkes, Ken Chen, Luis Muniz-Feliciano, Richard E. Champlin, Yago L. Nieto, Joachim Koch, Martin Treder, Wolfgang Fischer, Oswaldo Keith Okamoto, Elizabeth J. Shpall, Todd A. Fehniger, and Katayoun Rezvani

TABLE OF CONTENTS

3757 **A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors**

AC Xinyuan Lei, Zhanpeng Ou, Zhaohui Yang, Jianglong Zhong, Yanliang Zhu, Jing Tian, Jiannan Wu, Heran Deng, Xinyu Lin, Yu Peng, Bowen Li, Lile He, Zhiming Tu, Weixiong Chen, Qunxing Li, Niu Liu, Hanqing Zhang, Zhangsong Wang, Zezhen Fang, Teppei Yamada, Xiaobin Lv, Tian Tian, Guokai Pan, Fan Wu, Liping Xiao, Lizao Zhang, Tingting Cai, Xinhui Wang, Bakhos A. Tannous, Jinsong Li, Philippos Kontos, Soldano Ferrone, and Song Fan

3772 **The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients**

Bo Zheng, Xiao-Long Liu, Rong Fan, Jian Bai, Hao Wen, Lu-Tao Du, Guo-Qing Jiang, Chun-Ying Wang, Xiao-Tang Fan, Yi-Nong Ye, Yun-Song Qian, Ying-Chao Wang, Gao-Jing Liu, Guo-Hong Deng, Feng Shen, He-Ping Hu, Hui Wang, Qing-Zheng Zhang, Lan-Lan Ru, Jing Zhang, Yan-Hang Gao, Jie Xia, Hua-Dong Yan, Min-Feng Liang, Yan-Long Yu, Fu-Ming Sun, Yu-Jing Gao, Jian Sun, Chun-Xiu Zhong, Yin Wang, Fei Kong, Jin-Ming Chen, Dan Zheng, Yuan Yang, Chuan-Xin Wang, Lin Wu, Jin-Lin Hou, Jing-Feng Liu, Hong-Yang Wang, and Lei Chen

3784 **Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study**

Nicolien C. de Clercq, Tom van den Ende, Andrei Prodan, Robert Hemke, Mark Davids, Helle K. Pedersen, Henrik B. Nielsen, A.K. Groen, Willem M. de Vos, Hanneke W.M. van Laarhoven, and Max Nieuwdorp

3793 **Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis**

Lisa C. Holthof, Jort J. van der Schans, Afroditi Katsarou, Renée Poels, Anne T. Gelderloos, Esther Drent, Susan E. van Hal-van Veen, Fengzhi Li, Sonja Zweegman, Niels W.C.J. van de Donk, Maria Themeli, Richard W.J. Groen, and Tuna Mutis

CORRECTION

3804 **Correction: Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy**


Jingwei Sun, Qiao Lu, Miguel F. Sanmamed, and Jun Wang

AC AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a multiplex fluorescence IHC image of a patient with *PTEN* mutation in the phosphatase domain (best response: PD). CD204, CD3, and cytokeratin in cells are shown in *red*, *green*, and *orange*, respectively. Tumors with *PTEN* phosphatase domain mutations had higher levels of intratumoral CD204 macrophages. For details, see the article by Chida and colleagues on page 3714 of this issue.



Clinical Cancer Research

27 (13)

Clin Cancer Res 2021;27:3505-3804.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/27/13>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/27/13>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.